IMUX Immunic Inc.

14.12
-2.17  -13%
Previous Close 16.29
Open 15.4
Price To Book 15.69
Market Cap 142612000
Shares 10,100,000
Volume 96,928
Short Ratio
Av. Daily Volume 264,600

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim dosing analysis expected mid-2019 and full data readout expected 2Q 2020.
IMU-838
Ulcerative colitis
Phase 2 data due 2021.
IMU-838
Relapsing-remitting multiple sclerosis
Phase 2 trial to commence April 12, 2019.
IMU-838
Crohn’s disease